Johnson & Johnson Q2 2026 Earnings: Beat and Raise, But Shares Slip on MedTech Miss
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
/ 16 items
#JNJ↓
CMS Plans Permanent Medicare Drug Price Negotiations Starting 2029 – What It Means for Big Pharma
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
Johnson & Johnson Acquires Firefly Bio for $1B to Unlock New Cancer Treatments
The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue.
MeiraGTx Stock Drops After $100M Share Offering and Bota-Vec Buy from Johnson & Johnson
MeiraGTx stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches.
Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
J&J Eyes Big Sale of Its Orthopedics Business DePuy Synthes
Johnson & Johnson is exploring a potential $20B+ sale of its orthopedics unit DePuy Synthes instead of spinning it off, drawing interest from private equity firms in a major healthcare deal.